Arthritis, Rheumatoid

Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.

Tripterygium Wilfordii

Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.

Methotrexate

Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.

Yisaipu

Deptment of Rheumatology, Peking Union Medical College Hospital

Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA

Effectiveness and Safety of Tumor Necrosis Factor Receptor Fusion Protein(Yisaipu) Combined With Tripterygium Wilfordii for Active Rheumatoid Arthritis

The difference of ACR50 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12.

The difference of ACR20 and ACR70 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12.

The difference of ACR20, ACR50 and ACR70 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 24.

The change in DAS28 score from baseline to week 24 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX).
DAS28 ＝ 0.56*SQRT(TJC28) + 0.28*SQRT(SJC28) + 0.36*ln(CRP + 1) + 0.014*GH + 0.96
TJC28: The number of tender joints (0-28).
SJC28: The number of swollen joints (0-28).
CRP: The C-Reactive Protein level (in mg/l).
GH: The patient global health assessment (from 0=best to 100=worst).
The 28 joint: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and the knees.

The difference of proportions of patients meeting EULAR response between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12.

The change in HAQ-DI score from baseline to week 12 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX).
HAQ-DI is an index measuring the quality of life related to health, which includes 20 questions in terms of three categories:
from 0 to 1: mild difficulties to moderate disability,
from 1 to 2: disability moderate to severe,
from 2 to 3: severe to very severe disability.
The mean score is recorded as the result.

Xuan Zhang

Professor

Peking Union Medical College Hospital

Treatment of Arthritis

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems

Allopurinol

clinical trial was conducted in Bahawalpur, and Rawalpindi

Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine for the Management of Arthritis

Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine Arthitec 1 and Arthitec 2 With Allopathic Medicine for the Management of Arthritis

Reduction in Serum Uric Acid level will be monitored after 8 weeks. Increase level of Serum Uric acid is the major cause of Gouty arthritis which is more prevalent in South-Asian countries.

Hafiz Muhammad Asif

Assistant Professor

Shifa Ul Mulk Memorial Hospital

Rheumatoid Arthritis

It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).

Adalimumab

Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.

Healthy volunteers

Rennes University Hospital

Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis

Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis, With Analysis of CD4 + Follicular Helper T Subpopulations

Disease Activity Score 28 (DAS 28) calculated in every patients after clinical examination.

SDAI score will be calculated in every patients after clinical examination.

CDAI score will be calculated in every patients after clinical examination.

HAQ will be calculated in every patients after self-assessment questionnaire.

tripterygium bullockii/necrosis

Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA

Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine for the Management of Arthritis

Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht